Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COX-2s, Statins Have No Class In USP Medicare Draft Formulary

Executive Summary

U.S. Pharmacopeia has relegated some of the pharmaceutical industry's biggest blockbuster drug "classes" to the status of "recommended subdivisions" in its draft model Medicare formulary

You may also be interested in...



USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes

Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans

USP Final Formulary Guide Adds PPI Class, But Has Few Other Changes

Proton pump inhibitors may be the only commercially significant group of drugs to gain "pharmacologic class" status in the revisions to U.S. Pharmacopeia's model guidelines for Medicare drug plans

USP Responding To Congress’ Questions On Medicare Formulary Guidelines

The U.S. Pharmacopeia has been providing congressional committees with information as it moves toward finalizing its model formulary guidelines for the Medicare prescription drug benefit

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS044537

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel